Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mager

Showing results (31-40 of 90) with videos related to

Pageof 9
Sort By:
Chest|October 21, 2005
A pulmonary right-to-left shunt in patients with hereditary hemorrhagic telangiectasia is associated with an increased prevalence of migraineMartijn C Post, Tom G W Letteboer, Johannes J Mager, et al.
Nederlands Tijdschrift Voor Geneeskunde|October 2, 2014
[A young man with intestinal polyposis and epistaxis]Fred H Menko, Maarten A J M Jacobs, Johannes J Mager, et al.
Lung|October 5, 2019
Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?M C J van Thor, L Ten Klooster, R J Snijder, et al.
Clinical Science (London, England : 1979)|February 9, 2002
Quantification of right-to-left shunt with (99m)Tc-labelled albumin macroaggregates and 100% oxygen in patients with hereditary haemorrhagic telangiectasiaJohannes J Mager, Pieter Zanen, Fred Verzijlbergen, et al.
Respirology Case Reports|April 25, 2024
Pulmonary artery pseudoaneurysm after thoracic radiation therapy: A case report and review of the literatureGerdinique G C Maessen, Thijs T W Hoffman, Lidwien L Graat-Verboom, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|October 23, 2020
Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-seriesH Mathijssen, M P Huitema, A L M Bakker, et al.
Journal of Clinical Medicine|November 11, 2020
Hereditary Hemorrhagic Telangiectasia (HHT) and Survival: The Importance of Systematic Screening and Treatment in HHT Centers of ExcellenceEls M de Gussem, Steven Kroon, Anna E Hosman, et al.
Respiratory Medicine|March 1, 2022
Four-year survival rate in pulmonary sarcoidosis with extensive pulmonary hypertension screeningM P Huitema, H Mathijssen, A L M Bakker, et al.
Chest|February 16, 2010
Real prevalence of pulmonary right-to-left shunt according to genotype in patients with hereditary hemorrhagic telangiectasia: a transthoracic contrast echocardiography studyMarco W F van Gent, Martijn C Post, Repke J Snijder, et al.
Angiogenesis|November 19, 2020
Oral itraconazole for epistaxis in hereditary hemorrhagic telangiectasia: a proof of concept studyS Kroon, R J Snijder, A E Hosman, et al.
Pageof 9

Showing results (31-40 of 90) with videos related to

Sort By:
Pageof 9
Chest|October 21, 2005
A pulmonary right-to-left shunt in patients with hereditary hemorrhagic telangiectasia is associated with an increased prevalence of migraineMartijn C Post, Tom G W Letteboer, Johannes J Mager, et al.
Nederlands Tijdschrift Voor Geneeskunde|October 2, 2014
[A young man with intestinal polyposis and epistaxis]Fred H Menko, Maarten A J M Jacobs, Johannes J Mager, et al.
Lung|October 5, 2019
Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?M C J van Thor, L Ten Klooster, R J Snijder, et al.
Clinical Science (London, England : 1979)|February 9, 2002
Quantification of right-to-left shunt with (99m)Tc-labelled albumin macroaggregates and 100% oxygen in patients with hereditary haemorrhagic telangiectasiaJohannes J Mager, Pieter Zanen, Fred Verzijlbergen, et al.
Respirology Case Reports|April 25, 2024
Pulmonary artery pseudoaneurysm after thoracic radiation therapy: A case report and review of the literatureGerdinique G C Maessen, Thijs T W Hoffman, Lidwien L Graat-Verboom, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|October 23, 2020
Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-seriesH Mathijssen, M P Huitema, A L M Bakker, et al.
Journal of Clinical Medicine|November 11, 2020
Hereditary Hemorrhagic Telangiectasia (HHT) and Survival: The Importance of Systematic Screening and Treatment in HHT Centers of ExcellenceEls M de Gussem, Steven Kroon, Anna E Hosman, et al.
Respiratory Medicine|March 1, 2022
Four-year survival rate in pulmonary sarcoidosis with extensive pulmonary hypertension screeningM P Huitema, H Mathijssen, A L M Bakker, et al.
Chest|February 16, 2010
Real prevalence of pulmonary right-to-left shunt according to genotype in patients with hereditary hemorrhagic telangiectasia: a transthoracic contrast echocardiography studyMarco W F van Gent, Martijn C Post, Repke J Snijder, et al.
Angiogenesis|November 19, 2020
Oral itraconazole for epistaxis in hereditary hemorrhagic telangiectasia: a proof of concept studyS Kroon, R J Snijder, A E Hosman, et al.
Pageof 9